share_log

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

Stifel以买入评级启动对Cullinan Therapeutics的报道,宣布目标股价为40美元
Benzinga ·  05/01 05:49

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $40.

Stifel分析师布拉德利·卡尼诺以买入评级启动了对库里南疗法(纳斯达克股票代码:CGEM)的报道,并宣布目标股价为40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发